Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 12/20 | 0.42 |
| ▸ | CDC25B | P30305 | 10/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.42 |
| ▸ | CDC25A | P30304 | 3/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26658247 | 0.89 | TACR2 (0.44) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL30646414 | 0.88 | TACR2 (0.43) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL30646410 | 0.79 | TACR2 (0.45) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL26658237 | 0.77 | TACR2 (0.44) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL22704686 | 0.73 | TACR2 (0.51) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL22288934 | 0.70 | TACR2 (0.53) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL22288955 | 0.69 | PTPN1 (0.45) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL22288945 | 0.69 | TACR2 (0.56) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL15514995 | 0.68 | PTPN1 (0.55) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL26658233 | 0.68 | TACR2 (0.44) | TACR2NT5EPTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | PNP, NUDT1, ADAR | TACR2 4856/4885NT5E 34/4885PTPN1 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.